<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044380</url>
  </required_header>
  <id_info>
    <org_study_id>1200.48</org_study_id>
    <nct_id>NCT02044380</nct_id>
  </id_info>
  <brief_title>Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations</brief_title>
  <official_title>An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to evaluate the safety and tolerability of afatinib in
      patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring
      EGFR mutation(s) and have never been treated with an EGFR-TKI
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events according to Common Terminology Criteria (CTCAE Version 3).</measure>
    <time_frame>89 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>40, 30, or 20mg tablets taken once daily, dosage depending on tolerability</description>
    <arm_group_label>Afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)

          2. Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the
             institution's testing methodology

          3. Male or female patients age &gt;=18 years

          4. Adequate organ function, defined as all of the following:

               1. Absolute neutrophil count (ANC) &gt;1500/mm3

               2. Platelet count&gt;75,000/mm3

               3. Serum creatinine&lt;1.5 times of the upper limit of normal and/or creatinine
                  clearance (measured or calculated)&gt;45ml/min

               4. Total bilirubin &lt;1.5 times upper limit of (institutional) normal

               5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) &lt; three
                  times the upper limit of (institutional) normal (if related to liver metastases
                  &lt; five times ULN)

          5. Eastern Cooperative Oncology Group (ECOG)  score between 0-2

          6. Written informed consent by patient or guardian prior to admission into the trial
             that is consistent with International Conference on Harmonization (ICH)- Good
             Clinical Practice (GCP) guidelines and local law

        Exclusion criteria:

          1. Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)

          2. Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment
             (continued use of anti-androgens and/or gonadorelin analogues for treatment of
             prostate cancer permitted)

          3. Radiotherapy within 14 days prior to drug administration, except as follows:

               1. Palliative radiation to organs other than chest may be allowed up to 2 weeks
                  prior to drug administration, and

               2. Single dose palliative treatment for symptomatic metastases outside above
                  allowance to be discussed with sponsor prior to enrolling

          4. Major surgery within 4 weeks before starting trial treatment or scheduled for surgery
             during the projected course of the trial

          5. Known hypersensitivity to afatinib or any of its excipients

          6. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)
             classification of 3, unstable angina or poorly controlled arrhythmia as determined by
             the investigator. Myocardial infarction within 6 months prior to starting trial
             treatment

          7. Women of Child-Bearing Potential (WOCBP) and men who are able to father a child,
             unwilling to use adequate contraception prior to trial entry, for the duration of
             trial participation and for at least 2 weeks after treatment has ended

          8. Childbearing potential who:

               1. are nursing or

               2. are pregnant or

               3. are not using an acceptable method of birth control, or do not plan to continue
                  using this method throughout the trial and/or do not agree to submit to
                  pregnancy testing required by this protocol

          9. Any history of or concomitant condition that, in the opinion of the investigator,
             would compromise the patients ability to comply with the trial or interfere with the
             evaluation of safety for the trial drug

         10. Previous or concomitant malignancies at other sites, except effectively treated
             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ
             or effectively treated malignancy that has been in remission for more than 3 years
             and is considered to be cured

         11. Requiring treatment with any of the prohibited concomitant medications that cannot be
             stopped for the duration of trial participation

         12. Known pre-existing interstitial lung disease

         13. Presence of poorly controlled gastrointestinal disorders that could affect the
             absorption of the trial drug (e.g. CrohnÂ¿s disease, ulcerative colitis,
             malabsorption, or CTC grade =2 diarrhea of any aetiology) based on investigator
             assessment

         14. Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or
             HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA)
             and/or known Human Immunodeficiency Virus (HIV) carrier

         15. Meningeal carcinomatosis

         16. Symptomatic brain metastases (patients with asymptomatic brain metastases, who were
             previously treated, are eligible provided they have had Stable Disease (SD) for at
             least 4 weeks on stable doses of medication)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1200.48.00010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.48.00008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
